An Adaptable Platform for in-house Hepatitis C Serology

Jannie Pedersen, Irène Pegha Moukandja, Stella Ndidi, Anna-Louise Sørensen, Ismaël Hervé Koumakpayi, Jean-Bernard Lekana-Douki, Marie-Louise Vachon, Nina Weis, Gary Kobinger, Hugues Fausther-Bovendo

Abstract

Serology-based diagnosis remains one of the major tools for diagnosis and surveillance of infectious diseases. However, for many neglected diseases no or only few commercial assays are available and often with prices prohibiting large scale testing in low and middle-income countries (LMICs). We developed an adaptable enzyme-linked immunoassay (ELISA) using hepatitis C virus (HCV) as a proof-of-concept application. By combining the maltose-binding-protein with a multiepitope HCV protein, we were able to obtain a high concentration of protein suitable for downstream applications. Following optimization, the assay was verified using previously tested human samples from Canada, Denmark and Gabon in parallel with the use of a commercial protein. Sensitivity and specificity were calculated to 98% and 97% respectively, after accounting for non-specific binding and assay optimization. This study provides a thorough description of the development, and validation of a multiepitope ELISA-based diagnostic assay against HCV, which could be implemented at low cost. The described methodology can be readily adapted to develop novel ELISA-based diagnostic assays for other infectious pathogens with well-described immunogenic epitopes. This method could improve the diagnosis of neglected diseases for which affordable diagnostic assays are lacking.

OriginalsprogEngelsk
Artikelnummer114586
TidsskriftJournal of Virological Methods
Vol/bind308
Sider (fra-til)1-29
Antal sider29
ISSN0166-0934
DOI
StatusUdgivet - okt. 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'An Adaptable Platform for in-house Hepatitis C Serology'. Sammen danner de et unikt fingeraftryk.

Citationsformater